Pharma CEOs press case against drug price negotiation as bill gains support

The pharmaceutical industry could navigate the first years of Senate Democrats’ drug pricing plan if it becomes law, but longer term the bill could stifle development of new medicines, company executives warned in the latest round of earnings calls.